<DOC>
	<DOCNO>NCT01034488</DOCNO>
	<brief_summary>1 . Background : Heparin form complex plasma protein , antithrombin III ( ATIII ) endogenous anticoagulant . This complex inhibit formation thrombin accelerate destruction . In addition , heparin ATIII inactivate protease coagulation cascade , especially anti-activated factor X . The outcome biochemical action inhibition formation synthesis activator clot factor exert critical function genesis blood clot . Patients chronic renal failure ( CRF ) make use hemodialysis need system anticoagulation direct inhibitor thrombin / heparinoids prevent thrombosis . Based clinical study , control plasma heparin level patient CRF essential . Coagulation test APTT , PT , ChT evidence activity anti-Xa factor use substrate protection patient undergoing hemodialysis . 2 . Objective : Check non-inferiority clinical , pharmacodynamic effect safety use drug heparin porcine origin , produce Laboratory Eurofarma , active comparator drug APP Â® Heparin Sodium ( heparin - APP Pharmaceuticals ) patient renal failure hemodialysis treatment .</brief_summary>
	<brief_title>Pharmacodynamics Aspects Of Porcine Heparin Sodium , Produced Eurofarma , Compared Heparin Sodium , Produced APP Pharmaceuticasls , Patients With Chronic Renal Failure</brief_title>
	<detailed_description />
	<mesh_term>Calcium heparin</mesh_term>
	<mesh_term>Heparin</mesh_term>
	<criteria>Adults sex , regardless color social class ; Age 18 year , good clinical doctor 's discretion ; Patients research agree participate study sign inform consent form ( attach ) ; Chronic renal failure patient hemodialysis ( 3 time per week ) . chronic renal failure patient indication anticoagulation dialysis Non compliance term describe informed consent FICT ; Patients suffer sensitivity study heparin sodium ; Patients hypersensitivity search benzyl alcohol ; Patients search history bleeding disorder disease bleed disorder worsen terminate clinical picture , example , frame gastric ulcer ; Patients history research peptic ulcer ; Patient cancer research possibility impairment variable coagulation function ; Patients research pregnancy postpartum ; Individuals genetic abnormality coagulation system ; Trauma patient ; Patients glucocorticoid therapy least 1 month ; Patients use anticoagulant ; Patients high rate bleeding ; Patients undergo surgery perform less 15 day due risk bruise site surgery . Patients use drug affect hemostasis Patients use follow drug : Salicylates systemic aspirin NSAIDs , include ketorolac , Dextran 40 , ticlopidine clopidogrel , systemic glucocorticoid , thrombolytic agent anticoagulant antiplatelet agent , include antagonist glycoprotein IIb / IIIa .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2011</verification_date>
</DOC>